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Abstract Atherosclerotic carotid stenosis is an important
risk factor for stroke. Carotid plaques (CPs) causing stroke
may present a distinct type of molecular pathology
compared with transient ischemic attack (TIA)-associated
or asymptomatic plaques. We compared the gene expres-
sion profiles of CPs from stroke patients (n=12) and
asymptomatic patients (n=9), both with similar risk factors
and severity of carotid stenosis (>70%). Sixty probes
showed over 1.5-fold expression difference at 5% false
discovery rate. Functional clustering showed enrichment of
genes in 51 GO categories and seven pathways, the most
significant of which relate to extracellular-matrix interac-
tion, PPAR gamma signaling, scavanger receptor activity,
and lysosomal activity. Differential expression of ten genes
was confirmed in an extended replication group (n=43),
where the most significant expression differences were
found in CD36 (2.1-fold change, p=0.005), CD163 (1.7-
fold change, p=0.007) and FABP4 (2.2-fold change, p=
0.015). These include four genes not previously linked to
plaque destabilization: GLUL (2.2-fold change, p=0.016),
FUCA1 (2.2-fold change, p=0.025), IL1RN (1.6-fold
change, p=0.034), and S100A8 (2.5-fold change, p=
0.047). Strong correlations were found to plaque ulceration,
plaque hemorrhage, and markers of apoptosis and prolifer-
ation (activated caspase 3, TUNEL, and Ki67). Protein
expression of these genes was confirmed by immunohisto-
chemistry and was found in the atheromatous areas of CPs
critical for plaque destabilization. This study presents a
comprehensive transcriptional analysis of stroke-associated
CPs and demonstrates a significant transcriptome difference
between stroke-associated and asymptomatic CPs. Follow-
up studies on the identified genes are needed to define
whether they could be used as biomarkers of symptomatic
CPs or have a role in plaque destabilization.
Keywords Stroke.Atherosclerosis.Microarray.
Cerebrovascular.Real-time PCR
Introduction
Atherosclerotic disease of the internal carotid artery is a major
risk factor of ischemic stroke, and 20% of patients with
anterior and middle cerebral artery infarcts have significant
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differently; some progress to occlusion without causing any
symptoms, while others manifest themselves with a sudden
massive atherothromboembolic cerebral infarction. Previous
ipsilateral symptoms and stenosis of 70% or more are
established predictive factors of future ipsilateral stroke [1,
2]. Several histological features are also more frequent in
symptomatic carotid plaques (CPs), especially fibrous cap
thinning, greater inflammatory cell infiltrations, intraplaque
hemorrhage, and plaque rupture [3–6]. Both radiologically
and histologically detected ulcerations have been shown to
associate with symptoms [3, 5, 7]. The detailed molecular
mechanisms underlying these plaque features and CP
destabilization are incompletely understood.
Several studies have employed large-scale gene expres-
sion analysis as a tool to find novel pathophysiologically
important genes or signaling pathways that could trigger CP
destabilization. Vemuganti and Dempsey conducted a
whole genome microarray analysis of CPs from six
symptomatic and four asymptomatic patients and reported
289 differentially expressed genes [8], the significance of
which, however, is difficult to evaluate because of the lack
of adequate statistical tests or replication. In a slightly
different approach, Papaspyridonos and colleagues com-
pared unstable and stable plaque regions from three patients
and identified a large number of differentially expressed
genes in both intra- and inter-individual comparisons [9].
Twenty-seven of these were replicated in an independent
set of 46 unstable and stable plaque regions, and matrix
metalloproteinase-9 (MMP-9), cathepsin B, and legumain
further at the protein level. Dahl and colleagues compared
expression patterns in four symptomatic and four asymp-
tomatic CPs and found 136 genes with more than twofold
expression change, none of which were statistically
significant [10]. In subsequent studies in a replication
group of 21 CPs, they showed one of these genes, visfatin,
to be significantly over-expressed both at the RNA and
protein level in symptomatic CPs as well as strong protein
expression at the site of plaque rupture in acute coronary
syndrome patients. Recently, Agardh et al. compared the
expression profiles of CPs from patients with recent
symptom (≤1 month; n=14), patients with longer delay
(>1 month; n=17), and asymptomatic patients (n=9) and
showed the over-expression of fatty acid-binding protein 4
(FABP4) in CPs from patients with recent symptoms
compared to asymptomatic patients [11]. In addition to
FABP4, they report two other genes, IQ motif containing
GTPase-activating protein 1 and CD84 antigen, to be
upregulated in symptomatic CPs. Also proteomics
approaches utilizing a protein array of 512 antibodies [12]
and two-dimensional gel electrophoresis in connection with
mass spectrometry [13] have been used to compare protein
expression in stable and unstable carotid plaques. Despite
of a number of studies done, some limiting issues impede
drawing firm conclusions on the gene expression changes
typical of stroke-associated CPs: the very small number of
samples in some studies, diverse clinical diagnoses of
patients (amaurosis fugax, TIA, or stroke) and the small
number of findings reaching statistical significance.
Previously, we have carried out a microarray study on
rare cases of bilateral carotid stenosis when searching for
intra-individual local factors influencing plaque stability
and identified genes involved in the clearance of free tissue
hemoglobin, CD163 molecule (CD163), and heme
oxygenase-1, to be important [14]. Now we report a larger
microarray study of two extreme patient groups with similar
conventional risk factors and severity of carotid stenoses
but dissimilar clinical plaque behavior to identify inter-
individual differences. Due to the inherent inaccuracy in the
diagnosis of temporary symptoms such as in TIA and
recent findings suggesting that TIA or stroke may represent
distinct plaque pathologies [5, 6], we restricted our analysis
to stroke-associated carotid plaques (SCPs) from patients
with imaging-confirmed recent ipsilateral ischemic brain
infarct and asymptomatic carotid plaques (ACPs) from
patients without cerebrovascular symptoms and normal
brain imaging.
Materials and methods
Patients
The patients were selected from the Helsinki Carotid
Endarterectomy Study (HeCES) cohort, which included
92 patients who underwent carotid endarterectomy due to
high-grade carotid stenoses (>70% [1]) during 1997–2000
in the Helsinki University Central Hospital (methods in
detail [15–17]). Recruitment was in-group consecutive, i.e.,
the recruitment of asymptomatic patients continued
2 months longer to get a more balanced cohort symptom-
wise. All patients underwent thorough clinical examination
and interview by a stroke neurologist, DSA angiography,
transcranial Doppler ultrasound, brain imaging (CT or
MRI), routine blood analysis, and analysis of serum lipids
and fibrinolytic system. The clinical data was gathered in a
HeCES databank together with plaque-level histological
and gene expression data. The division into symptomatic or
asymptomatic CPs was based on the presence or absence of
prior ipsilateral ischemic cerebral or retinal symptoms
within 120 days prior to surgery. All human studies were
performed in accordance with the Declaration of Helsinki
and informed consent was obtained from all patients. The
study protocol was approved by the University of Helsinki
ethics committee of ophtalmology, otorhinolaryngology,
neurology, and neurosurgery (#339/E9/04).
1016 J Mol Med (2011) 89:1015–1026This microarray study includes CPs only from
symptomatic patients with clinical stroke and radiologi-
cally confirmed ischemic brain infarction in the ipsilat-
eral carotid territory (n=12) and asymptomatic patients
with no history of ischemic cerebral or retinal symptoms
and normal brain imaging (n=9). In addition, we
performed quantitative real-time RT-PCR in an extended
group of patients with a clinically defined ischemic stroke
or retinal infarct in the ipsilateral carotid territory (n=25)
and clinically asymptomatic patients (n=18). This group
of patients (n=43) is referred to as the “extended
replication group” in the text. There is a significant
gender difference between the stroke and asymptomatic
patients in both the microarray (p=0.023) and the
extended replication (p=0.055) groups. Patient character-
istics are given in Table 1.
Sample preparation
The CPs were removed en bloc in endarterectomy. The
vascular surgeon (ES) inspected CPs after gentle wash of
saline, and made macroscopic observations about surface
ulceration, intraplaque hemorrhage, intramural thrombus,
loose atheroma, and calcification. The plaques were cut into
five longitudinal slices, all containing a portion of atheroma
core, each of which were used for a specific purpose:
histological examination, RNA and protein extraction, and
biochemical analyses. Total RNA was extracted with
Trizol®-reagent (Invitrogen Life Technologies) and purified
with an RNeasy Total RNA Isolation Kit (Qiagen) accord-
ing to the manufacturers" recommendations. RNA quality
was assessed using the RNA 6000 Nano LabChip Kit
(Agilent Bioanalyser 2100; Agilent Technologies). Details
on RNA quality assessment can be found in Supplemental
Material.
Microarray analysis and quantitative real-time RT-PCR
The microarray experiments were performed according to
the manufacturer"s recommendations and the MIAME
guidelines [18] using Affymetrix GeneChip® U133A arrays
containing 22,283 probe sets. The flowchart of the micro-
array data analysis is shown in Fig. 1. Detailed description
on analysis steps can be found in Supplemental Material.
Quantitative real-time RT-PCR (qPCR) was performed
using TaqMan® Gene Expression Assays and the ABI
PRISM®7000 Sequence Detection System (Applied Bio-
systems) according to the manufacturer"s recommendations.
Beta-actin was used as the endogenous control gene and
relative quantitation was performed using either the
comparative delta–delta–Ct or the relative standard curve
method. For details see the Supplemental Material and
Supplemental Table 1.
Immunohistochemistry and microscopy
Microscopic analyses were performed in adjacent segments
of the plaques used for RNA extraction. CPs were assigned
to AHA-classes based on microscopic histology [19]. The
amounts of macrophages, activated T cells, mast cells, and
smooth muscle cells were determined by immunohisto-
chemistry [16]. In addition, the protein products of the
following genes were immunostained in the microarray
group either in fresh frozen or paraffin-embedded sections
using methods previously described [14, 15, 20]: CD36
molecule (CD36), perilipin 2 (PLIN2), FABP4, glutamate-
ammonia ligase (GLUL), chemokine (C–C motif) ligand 18
(CCL18), interleukin 1 receptor antagonist (IL1RN), heme
oxygenase 1 (HMOX1), and S100 calcium binding protein
A8 (S100A8; Supplemental Table 2). Light microscopy was
performed using Axioplan 2, AxioCam color, and MRGrab
1.0.0.4 respectively (all from Carl Zeiss) by one investiga-
tor (KN), who was blinded to the clinical data. For details
see Supplemental Material.
Statistics
The statistical analyses, apart from the microarray analyses,
were performed using SPSS10.0.7 for Windows (SPSS
Inc.). Pearson"s chi square or Fisher"s exact test was used to
evaluate the differences in non-continuous variables, and
the independent-samples t test was employed for continu-
ous variables. The results from qPCR were evaluated by the
Mann–Whitney U test. Correlations between real-time
qPCR results and clinical data and plaque characteristics
were calculated by nonparametric Spearman"s Rank Order
Correlation Coefficient with Benjamini–Hoechberg multi-
ple testing correction.
Results
Macroscopic and histological characterization of CPs
We first explored macroscopic and histological differences
between SCPs and ACPs. There were no differences in
macroscopic intraplaque hemorrhages, intramural throm-
bus, loose atheroma, or calcification. The SCPs had more
macroscopic ulcerations (Table 1). On microscopic exam-
ination, all CPs represented complicated AHA class VI
lesions containing microscopic surface ulceration (VIa),
hematoma/hemorrhage (VIb), and/or thrombotic deposit
(VIc, see Supplemental Figure 3)[ 19]. No significant
quantitative differences were found in the immunostained
area for macrophages, activated T cells, mast cell numbers,
or smooth muscle cell staining grades (Supplemental
Figures 4 and 5).
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1018 J Mol Med (2011) 89:1015–1026Microarray analysis
Figure 1 shows the flowchart of microarray analysis.
Firstly, we employed hierarchical clustering of all the CPs
and reliably expressed genes (n=3,433, see Fig. 1)t o
examine the relationships between CPs. The resulting
Condition tree (Fig. 2) shows two main branches, one
including ten of the 12 SCPs and the second, six of the nine
ACPs. Thus, the global gene expression profiles can
classify CPs according to the symptom to asymptomatic
and stroke-associated CPs. The classification accuracy
remains the same, if clustering is performed for all genes
(n=22,283, see Fig. 1).
Ninety-two reliably expressed genes (103 probe sets)
showed ≥1.5-fold expression difference between stroke-
associated and asymptomatic CPs (Supplemental Table 3).
SAM analysis [21] of the 103 probe sets showed that 60
probes sets were significantly differentially expressed at
5% false discovery rate (Table 2). Since microarray
analysis was shown to be sensitive to the choice of
preprocessing algorithm [22], we analyzed the hybridiza-
tion data also by two other commonly used algorithms,
GC-RMA [23] ,a n dM A S 5( http://www.affymetrix.com),
followed by comparable filtering steps (see Supplemen-
tal Material for details). Based on SAM analysis, 77 and
75 probe sets were significant at 5% FDR in GC-RMA
a n dM A S 5n o r m a l i z e dd a t a ,r e s p e c t i v e l y .T h i r t y - s e v e n
were shared by all three normalization methods (Sup-
plemental Figure 6).
Fig. 2 Hierarchical clustering of CPs (Condition tree). The samples
were classified into a tree based on their similarities. The length of the
branch between two samples indicates how correlated their expression
profiles are. The boxes below represent samples. The characteristics
that were unevenly distributed between symptomatic and asymptom-
atic groups are shown
Fig. 1 Microarray data analysis
flowchart. The number of probe
sets remaining after each analy-
sis step is shown. Dashed line
arrows to the right indicate
probe sets that were used for
different clustering analysis.
RMA Robust Multi-array Aver-
age. Asterisk (*) listed in Sup-
plemental Table 3
J Mol Med (2011) 89:1015–1026 1019Table 2 Microarray probe sets showing statistically significant expression difference between stroke-associated and asymptomatic carotid
plaques
Probe ID Gene symbol
a Gene name
a Fold-change Mann–Whitney U p
b SAM q (%)
b
202206_at ARL4C ADP-ribosylation factor-like 4 C 1.6 0.001 1.72
213418_at HSPA6 Heat shock 70 kDa protein 6 1.8 0.001 1.72
221760_at MAN1A1 Mannosidase, alpha, class 1A, member 1 1.5 0.002 1.72
210512_s_at VEGFA Vascular endothelial growth factor A 2.0 0.003 1.72
200921_s_at BTG1 B-cell translocation gene 1, anti-proliferative 1.6 0.004 1.72
202207_at ARL4C ADP-ribosylation factor-like 4C 1.6 0.004 1.72
212192_at KCTD12 Potassium channel tetramerisation domain containing 12 1.6 0.004 1.72
201670_s_at MARCKS Myristoylated alanine-rich protein kinase C substrate 1.6 0.006 1.72
202998_s_at LOXL2 Lysyl oxidase-like 2 1.7 0.006 1.72
218149_s_at ZNF395 Zinc finger protein 395 1.5 0.006 1.72
202499_s_at SLC2A3 Solute carrier family 2, member 3 1.7 0.009 1.72
205099_s_at CCR1 Chemokine (C–C motif) receptor 1 1.6 0.009 1.72
212154_at SDC2 Syndecan 2 1.8 0.009 1.72
217028_at CXCR4 Chemokine (C–X–C motif) receptor 4 1.8 0.009 1.72
202310_s_at COL1A1 Collagen, type I, alpha 1 1.7 0.011 1.72
212820_at DMXL2 DMX-like 2 1.7 0.011 1.72
201438_at COL6A3 Collagen, type VI, alpha 3 1.7 0.013 1.72
221210_s_at NPL N-acetylneuraminate pyruvate lyase 1.8 0.013 1.72
201193_at IDH1 Isocitrate dehydrogenase 1 (NADP+), soluble 1.6 0.016 1.72
202934_at HK2 Hexokinase 2 1.7 0.016 1.72
213655_at YWHAE Tyrosine 3-monooxygenase 1.6 0.016 1.72
215049_x_at CD163 CD163 molecule 1.6 0.016 1.72
217983_s_at RNASET2 Ribonuclease T2 1.7 0.016 1.72
32128_at CCL18 Chemokine (C–C motif) ligand 18 2.2 0.016 1.72
203645_s_at CD163 CD163 molecule 1.7 0.019 1.72
209924_at CCL18 Chemokine (C–C motif) ligand 18 2.0 0.019 1.72
212671_s_at HLA-DQA1/
HLA-DQA2/
LOC650946
Major histocompatibility complex, class II DQ alpha 1 1.8 0.019 1.72
201645_at TNC Tenascin C 1.6 0.023 1.72
202838_at FUCA1 Fucosidase, alpha-L-1 1.9 0.023 1.72
212582_at OSBPL8 Oxysterol binding protein-like 8 1.6 0.023 1.72
203814_s_at NQO2 NAD(P)H dehydrogenase, quinone 2 1.5 0.028 1.72
217202_s_at GLUL Glutamate-ammonia ligase 1.7 0.028 1.72
200648_s_at GLUL Glutamate-ammonia ligase 1.9 0.033 1.72
202087_s_at CTSL Cathepsin L 1.5 0.033 1.72
202436_s_at CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 1.6 0.033 1.72
202859_x_at IL8 Interleukin 8 1.9 0.033 1.72
202902_s_at CTSS Cathepsin S 1.5 0.033 1.72
204438_at MRC1/MRC1L1 Mannose receptor, C type 1 1.6 0.033 1.72
208146_s_at CPVL Carboxypeptidase, vitellogenic like 1.5 0.036 1.72
201147_s_at TIMP3 TIMP metallopeptidase inhibitor 3 1.9 0.039 1.72
202345_s_at FABP5 Fatty acid-binding protein 5 1.6 0.047 1.72
206488_s_at CD36 CD36 molecule 2.2 0.047 1.72
219607_s_at MS4A4A Membrane-spanning 4-domains, subfamily A, member 4 1.8 0.047 1.72
202912_at ADM Adrenomedullin 1.5 0.055 1.72
203665_at HMOX1 Heme oxygenase 1 2.2 0.055 1.72
203980_at FABP4 Fatty acid-binding protein 4 2.6 0.055 1.72
212657_s_at IL1RN Interleukin 1 receptor antagonist 1.6 0.055 1.72
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we performed gene enrichment analysis on Gene Ontology
(GO) categories and Kyoto Encyclopedia of Genes and
Genomes (KEGG) and Biocharta pathways for the differ-
entially expressed genes (n=103, Supplemental Table 3).
Fifty-one GO categories showed enrichment with the most
significant (p<0.001) categories: extracellular matrix, ex-
tracellular space, lysosome, lytic vacuole, vacuole, fibrillar
collagen, collagen, scavenger receptor activity, peptidogly-
can metabolism, response to wounding and organ develop-
ment (categories with ≥3 genes and p<0.01 are shown in
the Supplemental Figure 7 and Supplemental Table 4). Six
KEGG and one Biocharta pathway showed more than two
differentially expressed genes, and the most significant
pathways (p<0.001, in order of significance) were the
extracellular matrix-receptor interaction, PPAR signaling,
and antigen processing and presentation pathways (Supple-
mental Table 5).
Confirmation of differentially expressed genes
in the extended replication group
Differential expression of 18 genes discovered in the
microarray experiment was tested by qPCR in the same
samples and congruent fold change was found for 16 genes
(89%, Fig. 3). Next we analyzed these 18 genes in the
extended replication group (n=43), which included CPs
from clinically defined stroke patients (n=25) and asymp-
tomatic patients (n=18), and qPCR confirmed significant
differential expression of ten genes between SCPs and
ACPs (Fig. 3). Confirmed expression changes with the
most significant association (p<0.01) with symptoms were
CD36 (2.1-fold change, p=0.005) and CD163 (1.7-fold
change, p=0.007).
Correlations of differentially expressed genes
with clinical data and plaque features
We investigated whether the ten genes with confirmed
expression changes showed any association with clinical
patient characteristics or morphological plaque features
(Supplemental Table 6). After multiple testing correction,
we did not find significant associations to known athero-
sclerosis risk factors, comorbidities, medications, or plaque
cell-type markers. Instead, several genes showed associa-
tion to plaque ulceration (seven out of ten genes), intra-
plaque hemorrhage (four out of ten), and markers of cell
death and proliferation (activated caspase 3, four out of ten;
Ki67 proliferation marker, four out of ten; TUNEL
positivity in the intima, two out of ten). Additionally, three
genes showed positive correlation to the degree of ICA
stenosis.
Immunohistochemical verification of proteins encoded
by differentially expressed genes
The expression and histological localization of nine genes
(CD36, CD163, FABP4, PLIN2, GLUL, CCL18, IL1RN,
HMOX1, and S100A8) with qPCR-confirmed differential
expression in SCPs were investigated at the protein level
using immunohistochemistry (Fig. 4). CD36, CD163,
FABP4, PLIN2, HMOX1, GLUL, and S100A8 showed
expression mainly in macrophages. HMOX1, GLUL,
S100A8, and IL1RN were also expressed in other cell
Table 2 (continued)
Probe ID Gene symbol
a Gene name
a Fold-change Mann–Whitney U p
b SAM q (%)
b
214038_at CCL8 Chemokine (C–C motif) ligand 8 1.6 0.055 1.72
215223_s_at SOD2 Superoxide dismutase 2, mitochondrial 1.5 0.055 1.72
204580_at MMP12 Matrix metallopeptidase 12 2.3 0.065 1.72
209122_at PLIN2 Perilipin 2 1.8 0.065 1.72
217294_s_at ENO1 Enolase 1 1.7 0.065 1.72
200832_s_at SCD Stearoyl-CoA desaturase 1.6 0.076 1.72
209351_at KRT14 Keratin 14 1.8 0.076 1.72
209555_s_at CD36 CD36 molecule 1.9 0.076 1.72
201785_at RNASE1 Ribonuclease, RNase A family, 1 1.5 0.118 3.26
202917_s_at S100A8 S100 calcium binding protein A8 1.6 0.118 3.26
221730_at COL5A2 Collagen, type V, alpha 2 1.5 0.136 3.26
203381_s_at APOE Apolipoprotein E 1.6 0.177 4.00
204259_at MMP7 Matrix metallopeptidase 7 1.5 0.201 4.72
aFor the probe set detecting transcripts from several homologous genes, symbols are separated by hyphen. Gene name is only given for the first one
bp=pairwise non-adjusted p values from Mann–Whitney U test, q=the minimum false discovery rate at which the gene is called significant from
significance analysis of microarrays (SAM)
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IL1RN in smooth muscle cells and S100A8 in scarce
intimal polymorphonuclear cells. IL1RN was also
expressed in endothelial cells, both in the neovessels as
well as in the luminal endothelium. CCL18 showed a
diffuse intimal staining pattern typical for secreted chemo-
kines. CD36, CD163, FABP4, PLIN2, S100A8, HMOX1,
and GLUL showed strong staining around the lipid core
and in atheromatous areas.
Discussion
The evolution of an atherosclerotic CP into an unstable
plaque leading to atherothromboembolic strokes, is still
incompletely understood. We adopted large-scale micro-
array analysis to identify genes and cellular pathways that
could relate to plaque destabilization. Microarray analysis
was focused on two phenotypic extremes: symptomatic CPs
from patients with recent ipsilateral ischemic brain infarct
and asymptomatic CPs from patients that have never
experienced cerebrovascular symptoms and had normal
brain imaging. We demonstrate that stroke-associated CPs
possess a characteristic gene expression profile, which
distinguishes them from asymptomatic CPs. In addition to
confirming several previously recognized genes linked to
unstable atherosclerosis, our analysis revealed expression
changes in genes with no previously known association
with symptomatic or unstable atherosclerotic plaques.
Functional clustering data imply intrinsic differences
between ACPs and SCPs in cellular processes, including
inflammatory responses, intracellular lipid and carbohy-
drate metabolism and transport, lysosomal activity, and
reorganization of the extracellular matrix.
The microarray analysis revealed differential expression
with more than 1.5-fold change in 103 probe sets
representing 92 genes. SAM analysis of these 103 probe
sets found 60 probe sets to be statistically significant at 5%
FDR (Fig. 1 and Table 2). This represents approximately
Fig. 3 Confirmation of differential gene expression by qPCR. Genes
are organized according to statistical significance (significant bolded).
Microarray refers to non-adjusted p values from microarray analysis
also given in Table 2 and Supplemental Table 3. QPCR/microarray
refers to the real-time qPCR analysis results in the microarray group
and qPCR/replication in the extended replication group. All p values
from Mann–Whitney U test
Fig. 4 Immunohistochemical stainings of CD36, CD163, PLIN2,
FABP4, GLUL, CCL18, IL1RN, HMOX1, and S100A8. The first
column displays images obtained from the edge of an atheroma. The
second and the third columns are magnifications from foam cell-rich
areas indicated by rectangles

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number of differentially expressed genes are expected,
since we compare samples that all represent advanced
atherosclerotic tissue with no clear histological differences.
In addition, we used a stringent filtering criteria and
accepted 15% of the microarray probe sets for statistical
analysis. The decision on this high filtering cutoff was
based on a fact that in a heterogenous tissue such as
atherosclerotic plaque, any expression signal measured is a
sum of signals from numerous cell populations. Typically,
this leads to low fold changes, when only a proportion of
cells express a given gene or different cell population show
reverse expression changes overriding each others" effect. In
this kind of situation, detection of low fold “true” changes
from background fluctuation is difficult. Therefore, we
chose to concentrate on transcripts whose expression level
and difference are high enough to allow for their reliable
detection with a goal of finding reproducible list of
differentially expressed genes, even if we recognize that
this probably increases type II errors.
Eighteen genes were selected for replication by qPCR
both in the microarray group and in the extended
replication group. Several criteria were used in the
selection: statistical significance, consistency across pre-
processing methods, functional clustering analysis, and
novelty. Replication rate was 89% (16 out of 18 genes) in
the microarray group. Only ARL4C and HSPA6 failed to
show differential expression by qPCR despite being the two
most significant genes in the microarray analysis. Both
genes have only one exon, which might cause problems in
the correct measurement of single-exon genes by the array"s
probe design. Findings were similar in the extended
replication group: all except ARL4C and HSPA6 showed
congruent fold changes in magnitude and direction (Fig. 3).
The expression change was statistically significant for ten
of the 18 genes (56%). We confirmed protein expression of
these genes in the CPs by immunohistochemistry and show
that they are expressed in the atheromatous areas of CPs
critical for plaque destabilization (Fig. 4).
Many of the identified genes show correlation to plaque
features that can be considered markers of CP instability,
namely ulceration [5, 7], intraplaque hemorrhage [5], and
apoptosis [24] (Supplemental Table 6). In line with the
finding of the higher frequency of macroscopic ulcerations
in our stroke-associated CPs (see Table 1), the expression
of 80% of the qPCR-confirmed genes showed correlation to
macroscopic ulcerations. Plaque ulceration is an integral
phase in the development of sudden thromboembolism and
in this way a morphological correlate of plaque instability
[7, 25–27]. It is likely that ulceration affects gene
expression patterns and may partly explain them, i.e.,
through the process of wound healing. However, ulceration
and thromboembolism are not “one-time events” but rather
the unstable plaques have a chronic course of disease with
repeated thromboembolic events. For example, 36% of
patients in our extended replication group had TIA within
6 months prior to ischemic stroke and NASCET showed
that without CEA the risk of new event stays high several
months until it drops gradually within 2 to 3 years to the
same annual 3% level as found in asymptomatic patients
[1]. It is possible that the recurrent cycles of rupture and
healing with the concomitant ulceration of endothelial
lining and intraplaque hemorrhages are integral to the
instability of symptomatic plaques.
Seven of the qPCR-replicated genes also showed
correlation to intraplaque hemorrhages (IPH). In the large
meta-analysis of Gao and colleagues [28], incidence of IPH
was higher in symptomatic plaques, but the evidence
mainly derived from early small-sized studies, whereas
recent larger studies yielded insignificant associations. We
did not find difference in the incidence of IPH between
ACPS and SCPS in our study groups or in the whole
HeCES cohort (Table 1)[ 17]. However, these observations
do not exclude the role of IPH in plaque destabilization. In
patients with asymptomatic moderate carotid stenosis,
MRI-depicted IPH was associated with future ipsilateral
cerebrovascular events [27]. IPH or marked intraplaque
vessel formation were also shown to be the only plaque
features to predict cardiovascular events after CEA [29].
IPH can destabilize plaques both by ensuing oxidative and
inflammatory stress as well as exacerbating the local lipid
burden by entailing red blood cell membranes abundant in
cholesterol [14, 20, 30, 31]. Our own data suggests that IPH
lead to a more-pronounced inflammatory gene induction in
symptomatic than in asymptomatic CPs, which could be
explained by differences in genetic factors or plaque
microenvironment [14]. This kind of phenomenon could
explain ambiguous results from previous observational
studies.
The results obtained from the present study concur well
with the results from our earlier intra-patient expression
analysis [14] (15/92 (16%) of the differentially expressed
genes) as well as with the results from Papaspyridonos and
colleagues comparing unstable and stable plaque regions
[9] (33/92 (36%) of the differentially expressed genes).
Both matrix metallopeptidase 9 and legumain reported by
Papaspyridonos and colleagues [9] are significantly over-
expressed in the SCPs of our material. Instead, we do not
find increased expression of cathepsin B, but cathepsins D,
L, and S. We detect the strong over-expression of FABP4 in
the stroke-associated CPs, as was recently reported for
symptomatic CPs by two groups [11, 32]. Increased
expression of visfatin is not found in our material, but 20
of the genes showing differential expression (although not
reaching statistical significance) in the microarray study by
Dahl and colleagues [10], were also differentially expressed
1024 J Mol Med (2011) 89:1015–1026in our stroke-associated CPs. Converging evidence from
these studies accumulates for the important role of several
genes in the destabilization of CPs, especially cathepsin L,
CD36, fatty acid-binding proteins 4 and 5 (FABP4 and
FABP5), heme oxygenase 1, interleukin 1 receptor antag-
onist (IL1RN), interleukin 8, matrix metalloproteinases 7
and 12, N-acetylneuraminate pyruvate lyase (NPL), non-
muscle myosin 10 (MYH10) and perilipin 2 (PLIN2,
previously known as ADFP).
There is a significant difference between the proportion of
women in the symptomatic anda s y m p t o m a t i cg r o u p s
(Table 1). Skewed gender distribution is an inherent
epidemiological phenomenon incorporated in all consecutive
series of symptomatic carotid disease [1, 2]. In this study, the
gender difference is partly due to the fact that the microarray
analysis was restricted to the phenotypic extremes of the
disease defined by strict clinical and radiological criteria and
hence constituted a subgroup of the larger gender balanced
HeCES cohort. To partially compensate for the gender
imbalance, genes located in sex chromosomes were excluded
from the microarray data analysis. Despite of this imbalance,
RNA expression levels of only three of the 18 genes
replicated by qPCR showed any correlation to gender
(Supplemental Table 6). Also, hierarchical clustering of
samples based on global gene expression patterns show that
symptom and macroscopic ulcerations are stronger deter-
mining factors of gene expression than gender (Fig. 2).
In this study, we report a comprehensive transcriptional
analysis of CPs from individuals with clinically relevant
carotid disease that links plaque-level gene expression data
to thromboembolic strokes. Since the assignment to
symptom groups was performed purely from a clinical
standpoint, we consider the reported transcriptome to
genuinely represent clinical vulnerability of CPs. Perhaps
the most striking finding of the present study is that the
resulting transcriptome clearly differentiates stroke-
associated CPs from asymptomatic CPs at the level of
individual patients, corresponding to the clinical course
(Fig. 2). Unlike many systemic markers analyzed in our
patient material, the plaque-level analysis revealed significant
differences related to carotid plaque behavior. This indicates
that local expression changes within the plaque might be more
crucial in the longstanding development of plaque vulnerabil-
ity than incidental systemic factors that might have a more
transient triggering role in acute plaque destabilization. These
results suggest potential new pharmacological targets to be
explored for the management, stabilization, or treatment of
unstable large artery atherosclerosis.
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